Planned sale

Angiodynamics (ANGO): Officer filed to sell ~$290K

STEPHEN TROWBRIDGE, Officer at Angiodynamics, filed to sell ~$290K of Angiodynamics shares.

~$290K
planned to sell · 24K shares, around Oct 29, 2026

Planned for: Oct 29, 2026
Notice filed: Oct 29, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

Oct 2, 2026Company filing · Form 8-K · Material agreement, Executive changeChanged a top executive or board member, and signed an important agreement“On October 2, 2026, the Board of Directors of the Company (the “ Board ”) appointed Eric Honroth to serve as President and Chief Executive Officer of the Company, effective as of November 2, 2026 (the “ Effective Date ”) and concurrently with Mr. Clemmer’s retirement.”
Oct 8, 2026Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors
Oct 28, 2026InsiderCFO sold ~$21K of ANGO shares in the open market
Oct 29, 2026InsiderCFO sold ~$290K of ANGO shares in the open market

What came next

Oct 30, 2026FDAFDA device clearance: AngioVac F1885

View the official recordSEC Form 144

How to read SEC Form 144

Form 144 is a notice that a company insider plans to sell shares. It is filed when the sell order is placed, so it announces a planned sale and does not prove that the sale took place.

Full guide: What is an SEC Form 144?

What else is on file for Angiodynamics

For Angiodynamics, OQRO holds 3 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ANGO page.

How this filing works

Explore the data

Other disclosures at Angiodynamics

Everything OQRO holds on this company is on its ANGO page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data